What is Tango Therapeutics?
Founded in 2017 and headquartered in Boston, Massachusetts, Tango Therapeutics is a biotechnology firm dedicated to the discovery and development of novel medicines, with a primary focus on pioneering new cancer therapies. The company leverages its scientific expertise to identify and advance groundbreaking treatments aimed at addressing unmet medical needs in oncology. Tango Therapeutics operates within the dynamic and rapidly evolving field of precision medicine, seeking to translate scientific insights into tangible therapeutic solutions for patients.
How much funding has Tango Therapeutics raised?
Tango Therapeutics has raised a total of $455M across 4 funding rounds:
Private Equity
$50M
Other Financing Round
$165M
Stock/Share Issuance
$225M
Private Equity
$15M
Private Equity (2020): $50M with participation from Casdin Capital , LLC, Cormorant Asset Management , LLC, and Boxer Capital , LLC
Other Financing Round (2020): $165M, investors not publicly disclosed
Stock/Share Issuance (2025): $225M supported by Woodline Partners, Farallon, Balyasny Asset Management, and TCG Crossover
Private Equity (2025): $15M, investors not publicly disclosed
Key Investors in Tango Therapeutics
Woodline Partners
San Francisco-based Woodline Partners LP ("Woodline") is an investment firm implementing a market neutral equity strategy, focused on the global Healthcare and Technology sectors. Woodline's sub-sector Portfolio Manager model enables a focus on generating idiosyncratic alpha and avoiding systemic risk factors.
Farallon
Farallon is an investment management company that manages discretionary equity capital from institutional investors such as university endowments, foundations, and pension plans. The company was founded in 1986 and is headquartered in California.
Balyasny Asset Management
Balyasny Asset Management is a global investment firm focused on delivering consistent returns for institutional investors. The company uses deep research, advanced technology, and disciplined risk management to identify opportunities across financial markets, including equities, macro strategies, and quantitative trading while fostering a collaborative and performance driven culture.
What's next for Tango Therapeutics?
The substantial enterprise-level funding and recent strategic investment position Tango Therapeutics for accelerated growth and innovation. This capital infusion is anticipated to bolster research and development efforts, potentially enabling the company to advance its drug candidates through clinical trials and towards commercialization. The company's strategic focus on novel cancer therapies suggests a commitment to addressing challenging diseases, and this financing will be critical in supporting those ambitious goals. Tango Therapeutics is poised to make significant contributions to the oncology landscape.
See full Tango Therapeutics company page
